Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Dec 2005

Blum Roy, Kloog Yoel

Abstract excerpt

Constitutive activation of Ras pathways plays a critical role in cancer development and maintenance. Inhibitors of such pathways are already in use for cancer therapy, with significant but as yet only partial success in the most deadly types of human cancers, against which even combinations of Ras-pathway inhibitors with classic cytotoxic drugs or irradiation are insufficient. Combinations of farnesyl transferase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Enzyme Inhibitors

Share to Farnesyltranstransferase

Share to Oligonucleotides, Antisense

Share to Patient Selection

Share to ras Proteins

Source

Identifiers

PMID: 16356760
DOI: 10.1016/j.drup.2005.11.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.PMID 16356760Read ↗

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?Semantic proximity Read ↗

Past, Present, and Future of Targeting Ras for Cancer Therapies.Semantic proximity Read ↗

Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic TargetsSemantic proximity Read ↗

Combinatorial strategies to target RAS-driven cancers.Semantic proximity Read ↗

Finding and drugging the vulnerabilities of RAS-dependent cancers.Semantic proximity Read ↗

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.Semantic proximity Read ↗

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.Semantic proximity Read ↗

RAS: Circuitry and therapeutic targeting.Semantic proximity Read ↗

New druggable targets in the Ras pathway?Semantic proximity Read ↗

Evolving therapies: farnesyltransferase inhibitors.Semantic proximity Read ↗

Drugging RAS: Know the enemy.Semantic proximity Read ↗

Ras proteins as therapeutic targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.